Drugging the undruggable RAS: Mission Possible?
Open accessThe DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Abstract
Despite more than three decades of intensive effort, no effective pharmacological inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'. However, recent data from the laboratory and the clinic have renewed our hope for the development of RAS-inhibitory molecules. In this Review, we summarize the progress and the promise of five key approaches. Firstly, we focus on the prospects of using direct inhibitors of RAS. Secondly, we address the issue of whether blocking RAS membrane association is a viable approach. Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favourable current approach. Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise. Finally, RAS-mediated changes in cell metabolism have recently been described and we discuss whether these changes could be exploited for new therapeutic directions. We conclude with perspectives on how additional complexities, which are not yet fully understood, may affect each of these approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of highly selective and potent inhibitors have been developed against kinases in the Ras signaling network particularly those in the MAPK and PI3K/mTOR pathways (9, 12).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For more than 40 years, KRAS mutation has been considered “undruggable” [16, 17].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For many proteins known to be involved in driving diseases, such as KRAS in many cancers, conventional drug development strategies often aimed at developing inhibitors have failed [118, 119].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [119]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Research works printed but not linked: 1
- Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642–655 (2012). · DOI · Paper page
Cited by
Items 601–700 of 1,007
Zhang, X., Cao, J., Miller, S. P., Jing, H., & Lin, H. (2017) · ACS Central Science · doi:10.1021/acscentsci.7b00440 · Cited by 38
Fuentes, N. R., Mlih, M., Barhoumi, R., Fan, Y., Hardin, P. E., Steele, T. J., Behmer, S. T., Prior, I. A., Karpac, J., & Chapkin, R. S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0324 · Cited by 35
“Approximately 45% of colorectal cancers harbor KRas mutations (1), which confer resistance to standard therapy (2).”
BackgroundIntracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis
Liu, X., & Ghosh, D. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s212861 · Cited by 35
“Finally, these NPs were formulated to actively target the macropinocytic pathway for intracellular uptake in oncogenic RAS cancers; to fulfill the promise of these NPs for RAS-targeted therapy, it will be necessary to extend delivery to additional cancers with more canonical RAS mutations (eg, KRAS G12V, G12C; NRAS G1…”
BackgroundInfluentialTargeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine
Qian, L. M., Chen, K., Wang, C., Chen, Z., Meng, Z., & Wang, P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2604 · Cited by 36
“HRAS mutations (mainly G12 and Q61) are frequently associated with bladder cancer, and 20–30% of cutaneous melanomas are driven by NRAS Q61 mutations (36-38).”
BackgroundTargeting KRAS in Colorectal Cancer
Wang, C., & Fakih, M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01022-0 · Cited by 37
Waters, A. M., Khatib, T. O., Papke, B., Goodwin, C. M., Hobbs, G. A., Diehl, J. N., Yang, R. Y., Edwards, A. C., Walsh, K. H., Sulahian, R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109291 · Cited by 39
“, 2020), G12C comprises only 1%–2% of KRAS mutations in PDAC (Cox et al., 2014; Waters and Der, 2018).”
BackgroundSelf-citationSmall molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature
Thompson, S. K., Buckl, A. K., Dossetter, A. G., Griffen, E., & Gill, A. L. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1952984 · Cited by 35
Li, L., Liu, J., Yang, Z., Zhao, H., Deng, B., Ren, Y., Mai, R., Huang, J., & Chen, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114243 · Cited by 34
Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site
Murarka, S., Martín‐Gago, P., Schultz‐Fademrecht, C., Al Saabi, A., Baumann, M., Fansa, E. K., Ismail, S., Nussbaumer, P., Wittinghofer, A., & Waldmann, H. (2017) · Chemistry – A European Journal · doi:10.1002/chem.201603222 · Cited by 32
Ng, S., Juang, Y.-C. A., Chandramohan, A., Kaan, H. Y. K., Sadruddin, A., Yuen, T. Y., Ferrer‐Gago, F. J., Lee, X. C., Liew, X., Johannes, C. W., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00022 · Cited by 35
Emerging roles of i-motif in gene expression and disease treatment
Luo, X., Zhang, J., Gao, Y., Pan, W., Yang, Y., Li, X., Chen, L., Wang, C., & Wang, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1136251 · Cited by 39
“KRAS hyperactivation often results in sustained tumor proliferation, mostly common in lung, colorectal, and pancreatic carcinomas (Friday and Adjei, 2005; Baines et al., 2011; Cox et al., 2014).”
BackgroundTargeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Bteich, F., Mohammadi, M., Li, T., Bhat, M. A., Sofianidi, A. A., Wei, N., & Kuang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512030 · Cited by 36
“Once bound to GTP, KRAS actively transduces the signal from cell surface receptors such as Epithelial Growth Factor Receptor (EGFR) by binding to downstream effector proteins and ultimately causing cell growth and proliferation [32].”
BackgroundBiodegradable Hydrogen-Bonded Organic Framework for Cytosolic Protein Delivery
Chen, X., Zheng, Q., Cai, W., Sheng, J., & Wang, M. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c14450 · Cited by 34
Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors
Bear, A. S., Nadler, R. B., O’Hara, M. H., Stanton, K. L., Xu, C. B., Saporito, R., Rech, A. J., Baroja, M. L., Blanchard, T., Elliott, M. H., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175790 · Cited by 38
“The vast majority of KRAS mutations in these tumors occur at the codon 12 position (9), leading to hyper-activation of MAPK and PI3K-AKT downstream effector signaling pathways (10).”
Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs
Jackson, R. A., & Chen, E. S. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.014 · Cited by 42
Lee, K. H., Koh, M., & Moon, A. (2016) · Oncology Letters · doi:10.3892/ol.2016.4837 · Cited by 33
“N-Ras and K-Ras become substrates for geranylgeranyltransferase I, resulting in alternative prenylation and membrane targeting (9,13).”
InfluentialLocked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer
Ishige, T., Itoga, S., & Matsushita, K. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2017.10.002 · Cited by 39
Chen, K., Shang, Z., Dai, A.-L., & Dai, P.-L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117816 · Cited by 34
Sarkar, D., Olejniczak, E. T., Phan, J., Coker, J. A., Sai, J., Arnold, A. L., Beesetty, Y., Waterson, A. G., & Fesik, S. W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00511 · Cited by 33
Self-citationKumar, S. U., Bithia, R., Kumar, D. T., Doss, C. G. P., & Zayed, H. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1830177 · Cited by 36
“As a result, tumors with K-Ras mutations are often excluded from targeted therapies as they are impervious to standard therapies (Cox et al., 2014).”
BackgroundLigand decorated biodegradable nanomedicine in the treatment of cancer
Ahmad, E., Ali, A., Fatima, M. T., Nimisha, Apurva, A., Kumar, A., Sumi, M. P., Sattar, R. S. A., Mahajan, B., & Saluja, S. S. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105544 · Cited by 35
Kazi, A., Chen, L., Xiang, S., Vangipurapu, R., Yang, H., Beato, F., Fang, B., Williams, T. M., Husain, K. M., Underwood, P. W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4781 · Cited by 33
Garrigou, M., Sauvagnat, B., Duggal, R., Boo, N., Gopal, P., Johnston, J. M., Partridge, A. W., Sawyer, T. K., Biswas, K., & Boyer, N. C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00154 · Cited by 36
Ha, S., Zhu, J., Xiang, H., & Luo, G. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109192 · Cited by 37
Bigenzahn, J. W., Fauster, A., Rebsamen, M., Kandasamy, R. K., Scorzoni, S., Vladimer, G. I., Müller, A. C., Gstaiger, M., Zuber, J. A., Bennett, K. L., et al. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o115.055350 · Cited by 35
“Here, we demonstrated efficiency and applicability of pRSHIC for TAP-MS-based interaction proteomics studies on the oncogenic NRAS G12D mutant protein (22) in murine Ba/F3 cells.”
Myotubularin-related protein 7 inhibits insulin signaling in colorectal cancer
Weidner, P., Söhn, M., Gutting, T., Friedrich, T., Gaiser, T., Magdeburg, J., Kienle, P., Ruh, H., Hopf, C., Behrens, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10466 · Cited by 35
“Thus, new drugable targets that inhibit RTK signaling are needed [8].”
BackgroundYe, X., Chan, K. C., Waters, A. M., Bess, M., Harned, A., Wei, B., Lončarek, J., Luke, B. T., Orsburn, B. C., Hollinger, B. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13566 · Cited by 35
“However, this knowledge has not been translated into effective treatment of cancers driven by oncogenic KRas, which includes approximately 95% of pancreatic and approximately 40% of colon and lung carcinomas [2].”
BackgroundQuantitative Measurement of Intrinsic GTP Hydrolysis for Carcinogenic Glutamine 61 Mutants in H-Ras
Novelli, E. T., First, J. T., & Webb, L. J. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00878 · Cited by 33
Karimi, N., & Moghaddam, S. J. (2023) · Cells · doi:10.3390/cells12050749 · Cited by 39
“However, these findings face various limitations in their application to the human cancer cell [83].”
BackgroundExploring Protein S-Palmitoylation: Mechanisms, Detection, and Strategies for Inhibitor Discovery
Pei, S., & Piao, H. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00110 · Cited by 37
Targeting the α4-α5 interface of RAS results in multiple levels of inhibition
Spencer-Smith, R., Li, L., Prasad, S., Koide, A., Koide, S., & O’Bryan, J. P. (2017) · Small GTPases · doi:10.1080/21541248.2017.1333188 · Cited by 34
“KRAS is the most frequently mutated RAS isoform in human cancers, with mutations predominating in cancers of the pancreas, lung, and colon.(1,5,6) For these reasons RAS has become one of the highest priority tar-”
BackgroundInfluentialSheffels, E., Sealover, N. E., Theard, P. L., & Kortum, R. L. (2019) · Small GTPases · doi:10.1080/21541248.2019.1611168 · Cited by 31
Li, J., Li, H., Zhu, W., Zhou, B., Ying, J., Wu, J., Zhang, H., Sun, H., & Gao, S. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14813 · Cited by 32
Pathogenesis of bowel endometriosis
Yong, P. J., Bedaiwy, M. A., Alotaibi, F. T., & Anglesio, M. S. (2020) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2020.05.009 · Cited by 40
Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Du, R., Sullivan, D. K., Azizian, N. G., Liu, Y., & Li, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-07967-6 · Cited by 34
Targeting RAS oncogenesis with SOS1 inhibitors
Hillig, R. C., & Bader, B. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.001 · Cited by 39
Chatzigoulas, A., & Cournia, Z. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab518 · Cited by 32
KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
Ceddia, S., Landi, L. M., & Cappuzzo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169391 · Cited by 40
Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
Shaya, J. A., Kato, S., Adashek, J. J., Patel, H., Fanta, P. T., Botta, G. P., Sicklick, J. K., & Kurzrock, R. (2023) · npj Genomic Medicine · doi:10.1038/s41525-022-00346-5 · Cited by 33
Saiyin, H., Na, N., Han, X., Fang, Y., Wu, Y., Lou, W., & Yang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.17965 · Cited by 35
Kim, S. Y., & Kim, T. W. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000634 · Cited by 35
Fragment-based drug discovery of triazole inhibitors to block PDEδ-RAS protein-protein interaction
Chen, D., Chen, Y., Lian, F., Chen, L., Li, Y., Cao, D., Wang, X., Chen, L., Li, J., Meng, T., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.018 · Cited by 31
Epigenetic basis of oncogenic-Kras-mediated epithelial-cellular proliferation and plasticity
Murthy, P. K. L., Xi, R., Mendoza, D. A., Everitt, J. I., Koçak, D. D., Kobayashi, Y., Bözec, A., Vicent, S., Ding, S., Crawford, G. E., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.01.006 · Cited by 31
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
“2.4.5 | KRAS‐targeting PROTACs KRAS is a GTPase encoded by kirsten rat sarcoma viral oncogene homologue (KRAS) gene which is frequently mutated in cancers (Prior et al., 2012).”
BackgroundInfluentialDaley, B. R., Vieira, H. M., Rao, C., Hughes, J. M., Beckley, Z., Huisman, D. H., Chatterjee, D., Sealover, N. E., Cox, K., Askew, J. W., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313137120 · Cited by 32
“5 Main Text Introduction RAS proteins are encoded by three paralogs, KRAS, NRAS, and HRAS, which are, collectively, the most frequently mutated oncogene in cancer (1, 2).”
BackgroundMethodWang, Y., Hedblom, A., Koerner, S. K., Li, M., Jernigan, F. E., Wegiel, B., & Sun, L. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.10.063 · Cited by 32
RNA Interference-Based Cancer Drugs: The Roadblocks, and the “Delivery” of the Promise
Das, M., Musetti, S., & Huang, L. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0762 · Cited by 32
“KRas driven cancers such as PDAC remain challenging to treat, ‘‘undruggable’’ [37], and subsequently, these trials using an RNAi approach against oncogenes arose optimism.”
BackgroundAthauda, A., Fong, C., Lau, D. K., Javle, M. M., Abou‐Alfa, G. K., Morizane, C., Steward, K., & Chau, I. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101998 · Cited by 33
“Although mutant KRAS is a well-recognised oncogenic driver across various malignancies, direct targeting of RAS has been unsuccessful to date including in BTC [75].”
BackgroundD’Aria, F., D’Amore, V. M., Leva, F. S. D., Amato, J., Caterino, M., Russomanno, P., Salerno, S., Barresi, E., Leo, M. D., Marini, A. M., et al. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105337 · Cited by 33
Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy
Tian, D., Tang, J., Geng, X., Li, Q., Wang, F., Zhao, H., Narla, G., Yao, X., & Zhang, Y. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.08.008 · Cited by 35
“However, these targets may only apply to a small subset of KRAS mutations in a context dependent manner and clinical validation is still needed [1,2].”
BackgroundInfluentialRAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics
Kattan, W. E., & Hancock, J. F. (2020) · Biochemical Journal · doi:10.1042/bcj20190839 · Cited by 36
Murta, T., Steven, R. T., Nikula, C. J., Thomas, S. A., Zeiger, L. B., Dexter, A., Elia, E. A., Yan, B. L., Campbell, A. D., Goodwin, R. J. A., et al. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.0c04179 · Cited by 34
Ryu, W., Han, G., Lee, S.-H., & Choi, K. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.076 · Cited by 32
Weng, N., Qin, S., Liu, J., Huang, X., Jiang, J., Zhou, L., Zhang, Z., Xie, N., Wang, K., Jin, P., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.018 · Cited by 32
Hou, Y., Gan, T., Fang, T., Zhao, Y., Luo, Q., Liu, X., Qi, L., Zhang, Y., Jia, F., Han, J., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac151 · Cited by 37
Li, M.-Y., Wang, Y., Fan, J., Zhuang, H., Liu, Y., Ji, D., & Lu, S. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167730 · Cited by 30
Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors
Rathod, L. S., Dabhade, P. S., & Mokale, S. N. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103557 · Cited by 33
MicroRNAs: Modulators of theRasOncogenes in Oral Cancer
Murugan, A. K., Munirajan, A. K., & Alzahrani, A. S. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25269 · Cited by 34
“…deregulated and is an important therapeutic target in human cancers including OSCC, discovering and targeting using a small molecule inhibitor against the ras became more unrealistic due to its unique features (Karnoub andWeinberg, 2008; Murugan et al., 2009, 2012; Cox et al., 2014; Ledford, 2015).”
BackgroundCombined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics
Lang, L., Shay, C., Zhao, X., & Teng, Y. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0583-4 · Cited by 32
“Ras is considered as “undruggable” because it lacks a well-defined binding pocket in the Ras protein structure to accommodate a biologically active small molecule [12, 13].”
Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A
Zhao, H., Liu, P., Zhang, R., Wu, M. H., Li, D., Zhao, X., Zhang, C., Jiao, B., Chen, B., Chen, Z., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0226-1 · Cited by 33
“Aberrant activation of the RAS signaling pathway is common in cancer, including 20–30 % cancers with RAS mutations [4].”
BackgroundInfluentialK-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
Nussinov, R., Muratcioğlu, S., Tsai, C., Jang, H., Gürsoy, A., & Keskin, Ö. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1135131 · Cited by 32
“K- and N-Ras.[7] Targeting combinations of pathways also culminated in toxicity, and results based on the principle of synthetic”
BackgroundInfluentialCCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma
Cai, Y., Li, X., Shen, P., & Zhang, D. (2018) · Biological Research · doi:10.1186/s40659-017-0149-0 · Cited by 30
“Although KRAS signaling is perceived as the major driving force of PDAC [7], intensive effort to explore KRAS as effective therapeutic target in PDAC has largely failed to reach the clinic [8].”
Birgani, M. J. T., Teimoori, A., Ghadiri, A., Asl, H. M., Danyaei, A., & Khanbabaei, H. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28148 · Cited by 31
“This activating mutation drives KRAS constitutively active with acquired oncogenic features.(34) KRASmut is associated with poor prognosis in various malignancies.”
BackgroundInfluentialToyama, Y., Kontani, K., Katada, T., & Shimada, I. (2019) · Science Advances · doi:10.1126/sciadv.aav8945 · Cited by 31
Klein, C. H., Truxius, D. C., Vogel, H. A., Harizanova, J., Murarka, S., Martín‐Gago, P., & Bastiaens, P. I. H. (2018) · International Journal of Cancer · doi:10.1002/ijc.31859 · Cited by 32
“class with prevalent (45%) oncogenic KRas mutations.(3) To date, targeted therapy with monoclonal antibodies against EGFR, such as Cetuximab, is a major alternative to systemic cytotoxic chemotherapy in CRC.”
BackgroundHenry, J. T., & Johnson, B. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.08.08 · Cited by 29
Chen, F., Li, X., Zhu, H.-P., & Huang, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00280 · Cited by 33
“pathway in antitumor drug treatment mainly include directly targeting Ras proteins, inhibiting processes related to translation or modification, and inhibiting the downstream molecules of the Ras-Related signaling pathway (Tamanoi and Lu, 2013; Cox et al., 2014).”
BackgroundThe RAL signaling network: Cancer and beyond
Apken, L. H., & Oeckinghaus, A. (2020) · International review of cytology · doi:10.1016/bs.ircmb.2020.10.005 · Cited by 32
Targeting KRAS in Non-Small Cell Lung Cancer
Corral de la Fuente, E., Olmedo Garcia, M. E., Gomez Rueda, A., Lage, Y., & Garrido, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.792635 · Cited by 30
“1 KRAS G12C (OFF) Inhibitors KRAS proteins are small proteins with a relatively smooth molecular surface without readily accessible binding pockets, with a high affinity for GDP/GTP and complex downstream pathways (5, 43, 44).”
BackgroundInfluentialShen, M., Qi, R., Ren, J., Lv, D., & Yang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780655 · Cited by 33
“At the same time, direct KRAS targeting and KRAS-related immunotherapy have also made great progress (14, 15).”
BackgroundInhibition of SHP2 as an approach to block RAS-driven cancers
Chou, Y., & Bivona, T. G. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.002 · Cited by 33
Ramalingam, P. S., Balakrishnan, P., Rajendran, S., Jothi, A., Rajasekaran, R., & Arumugam, S. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45030137 · Cited by 36
“In addition, the in silico cell-line-toxicity prediction suggests that our four leads could possess cytotoxicity against the pancreatic, lung, and colon cancers in which the KRAS is highly mutated [42,43].”
BackgroundLuo, G., Wang, B., Hou, Q., & Wu, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01729 · Cited by 30
Röth, S., Kocatürk, N. M., Sathyamurthi, P. S., Carton, B., Watt, M., Macartney, T., Chan, K.-H., Isidro‐Llobet, A., Konopacka, A., Queisser, M. A., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2023.07.006 · Cited by 34
Nastasă, C., Tamaian, R., Oniga, O., & Tiperciuc, B. (2019) · Medicina · doi:10.3390/medicina55040085 · Cited by 31
“The products of KRAS and NRAS genes (K-Ras and N-Ras isoforms) belong to the Ras proteins family [7,11,15,18] and are both small GTPases, having a 189 amino acids (AAs) length.”
BackgroundScreening-based approaches to identify small molecules that inhibit protein–protein interactions
Choi, S., & Choi, K.-Y. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1280456 · Cited by 29
“For example, DCAI (4,6dichloro-2-methyl-3-aminoethyl-indole) represents a significant advancement in inhibitors of Ras oncogene and indicates anticancer effects by blocking the Ras–SOS1 interaction [38,39].”
BackgroundNon-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit
Ning, W., Marti, T. M., Dorn, P., & Peng, R.-W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1004669 · Cited by 29
“Ironically, unlike the oncoproteins EGFR and ALK, which are less prevalently altered in NSCLC, there are few targeted therapies for KRAS-mutant NSCLC, and few clinical studies have specifically addressed this largest NSCLC subpopulation (6, 7).”
BackgroundOne reporter for in-cell activity profiling of majority of protein kinase oncogenes
Gudernová, I., Foldynová-Trantírková, S., Ghannamova, B. E., Fafílek, B., Vařecha, M., Bálek, L., Hrubá, E., Jonatova, L., Jelínková, I., Bosakova, M. K., et al. (2017) · eLife · doi:10.7554/elife.21536 · Cited by 29
“Lastly, several important oncogenes and downstream targets of RTK signaling, such as RAS, appear not druggable directly (Cox et al., 2014) and thus the inhibitors of their signaling may only be discovered via in-cell activity profiling.”
Inhibition of prenylated KRAS in a lipid environment
Jansen, J. M., Wartchow, C. A., Jahnke, W., Fong, S. K., Tsang, T., Pfister, K. B., Zavorotinskaya, T., Bussiere, D. E., Cheng, J. M., Crawford, K. R., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174706 · Cited by 30
“For the past 3 decades, many strategies have been devised and executed to pharmacologically target mutant-RAS tumors, including strategies to inhibit RAS directly, to interfere with correct localization of RAS, or to inhibit effector pathways downstream of RAS [10–12].”
Advancements in CRISPR/Cas9 technology—Focusing on cancer therapeutics and beyond
Mirza, Z., & Karim, S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.026 · Cited by 31
Talebi, A., Masoodi, M., Mirzaei, A., Mehrad‐Majd, H., Azizpour, M., & Akbari, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29083 · Cited by 29
Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRASG12C
Mortier, J., Friberg, A., Badock, V., Moosmayer, D., Schroeder, J., Steigemann, P., Siegel, F., Gradl, S., Bauser, M., Hillig, R. C., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.201900727 · Cited by 29
Capturing the primordial Kras mutation initiating urethane carcinogenesis
Li, S., MacAlpine, D. M., & Counter, C. M. (2020) · Nature Communications · doi:10.1038/s41467-020-15660-8 · Cited by 32
Inhibition of Nonfunctional Ras
Nussinov, R., Jang, H., Gürsoy, A., Keskin, Ö., & Gaponenko, V. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.012 · Cited by 30
“The diverse strategies of potential Ras inhibitors have been reviewed extensively in the literature (Chatani and Yang, 2020; Cox et al., 2015; Cox et al., 2014; Dang et al., 2017; Gentile et al., 2017; Gorfe and Cho, 2019; Gupta et al., 2019; Khan et al., 2020a; Liu et al., 2010; Liu et al., 2019; Lu et al., 2016a; Lu…”
BackgroundInfluentialAdvances in Targeted Therapy and Immunotherapy for Pancreatic Cancer
Liu, X., Li, Z., & Wang, Y. (2021) · Advanced Biology · doi:10.1002/adbi.201900236 · Cited by 30
Mechanism of activation and the rewired network: New drug design concepts
Nussinov, R., Zhang, M., Maloney, R., Tsai, C., Yavuz, B. R., Tunçbağ, N., & Jang, H. (2021) · Medicinal Research Reviews · doi:10.1002/med.21863 · Cited by 31
Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies
Shetu, S. A., & Bandyopadhyay, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073706 · Cited by 32
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
Puccini, A., Seeber, A., & Berger, M. D. (2022) · Cancers · doi:10.3390/cancers14194828 · Cited by 31
“For a long time, RAS mutations have been deemed ‘undruggable’ [82], as many attempts targeting RAS mutations failed in the past.”
BackgroundThe renewed battle against RAS-mutant cancers
Zhang, F., & Cheong, J. K. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2155-8 · Cited by 32
From Ras to Rap and Back, a Journey of 35 Years
Bos, J. L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031468 · Cited by 33
“These studies have recently been discussed by Cox and coworkers (Cox et al. 2014).”
BackgroundInformatics Approaches for Predicting, Understanding, and Testing Cancer Drug Combinations
Tang, J. P. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7154-1_30 · Cited by 30
“Furthermore, many known driver genes are not pharmacologically druggable as there is a lack of available drugs in the clinics [4].”
BackgroundSau, S., Tatiparti, K., Alsaab, H. O., Kashaw, S. K., & Iyer, A. K. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.03.003 · Cited by 30
“Several strategies including direct mKRas inhibitors and mKRas effector protein inhibitors have been developed for more than three decades to suppress mKRas function but no potent inhibitors have entered the clinic, which led to the perception that KRas protein was undruggable [82].”
BackgroundZhang, F., & Cao, H. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4655 · Cited by 30
KRAS regulation by small non-coding RNAs and SNARE proteins
Che, Y., Siprashvili, Z., Kovalski, J. R., Jiang, T., Wozniak, G. G., Elcavage, L. E., & Khavari, P. A. (2019) · Nature Communications · doi:10.1038/s41467-019-13106-4 · Cited by 35
CRISPR Diagnosis and Therapeutics with Single Base Pair Precision
Lee, S. H., Park, Y., Jin, Y. B., Kim, S., & Hur, J. K. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.09.008 · Cited by 33
Biology, pathology, and therapeutic targeting of RAS
Rhett, J. M., Khan, I., & O’Bryan, J. P. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.05.002 · Cited by 31
“Design of inhibitors targeting the nucleotide pocket has not been considered possible due to the picomolar affinity of RAS for nucleotides coupled with the millimolar levels of guanine nucleotides in cellulo (Cox et al., 2014).”
BackgroundSomade, O. T., Ajayi, B. O., Olunaike, O. E., & Jimoh, L. A. (2020) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2020.100806 · Cited by 29
“Ras on the other hand, is one of the most common and often mutated oncogenes in human cancer but the frequency and distribution of mutations are not uniform [68,69].”
BackgroundRas isoform-specific expression, chromatin accessibility, and signaling
Nussinov, R., Zhang, M., Maloney, R., & Jang, H. (2021) · Biophysical Reviews · doi:10.1007/s12551-021-00817-6 · Cited by 32
“They predominate in different cancer types and the distributions of the mutations differ as well (Cox et al. 2014; Hobbs et al. 2016; Li et al. 2018a; Prior et al. 2012).”
BackgroundHan, Y., Yu, C.-C., Fine, S. A., Youssof, A. L., Yang, Y., Yan, J., Karg, D. C., Cheung, E. C., Friedman, R. A., Ying, H., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02040-9 · Cited by 28
“As the result, there has been a renewed interest in targeting the once thought to be undruggable KRAS [3, 4].”
BackgroundSelf-citationShin, D. H., Kim, S. H., Choi, M., Bae, Y., Han, C., Choi, B. K., Kim, S. S., & Han, J. (2021) · Oncogene · doi:10.1038/s41388-021-02097-6 · Cited by 29
“Unless these observations, the development and clinical action of specific KRAS inhibitors have proven technically challenging, and we give the effort to identify druggable cooperating partners of oncogenic KRAS [7].”
Background
Metadata
- Authors
- Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Vanderbilt University (US)
- Dana-Farber Cancer Institute (US)
- National Cancer Institute (US)
- Corresponding author
- Der, Channing J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-10-17
- Volume
- 13
- Issue
- 11
- Pages
- 828-851
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4355017
- OpenAlex
- W2081990599
- Cited by
- 1,997
- References
- 231
- Citations by year
- 2026: 134 · 2025: 160 · 2024: 194 · 2023: 185 · 2022: 213 · 2021: 237 · 2020: 204 · 2019: 166 · 2018: 156 · 2017: 166 · 2016: 106 · 2015: 71 · 2014: 2
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (DP1OD006933, 5r01ca042978-30)
- U.S. Public Health Service (P50A095103-12)
- National Cancer Institute (P50CA127003, CA042978, R01CA175747, DP1CA174419, P50CA095103, CA175747, R01-CA042978, R21CA179193, RC2CA148375, CA179193, R01CA157490)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RAS inhibitors, undruggable targets, synthetic lethality, RAS-mutant cancers, anticancer drug discovery, Ras signaling
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Signal Transduction, Oncogene Proteins, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.